Customize your experience

You decide what information you want to see on your Sanofi Campus

More about science

Choose a therapeutic area to find related scientific content

Diabetes

Thrombosis

Kidney Transplant

CNS

Respiratory Disease

Otolaryngeal Disorders

Latest trends

Explore the most popular scientific content among Sanofi Campus users

Support for your patients

Discover the selection of support materials for patients from different therapeutic areas

Our Products

Allegra® 120

Allegra® 120 mg tablets (Fexofenadine Hydrochloride Tablets IP 120 mg) are the second-generation antihistamine tablets indicated for the relief of symptoms associated with allergic rhinitis and chronic idiopathic urticaria.

Allegra® 180

Allegra®  180 mg tablets (Fexofenadine Hydrochloride Tablets IP 180 mg) are the second-generation antihistamine tablets indicated for the relief of symptoms associated with allergic rhinitis and chronic idiopathic urticaria.

Allegra®-M

Allegra®-M tablets (Fexofenadine Hydrochloride and Montelukast Tablets) are indicated for the treatment of allergic rhinitis in adults and adolescents 15 years of age and older.

 

Allegra® Suspension

Allegra® Suspension (Fexofenadine Hydrochloride Suspension) is indicated for relief of symptoms associated with allergic rhinitis in children 2-11 years of age and uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 11 years of age.

Allegra® Nasal

Allegra® Nasal is indicated for the treatment of symptoms of allergic rhinitis. The dosage for adults and adolescents 12 years and over is 110 mcg (two sprays in each nostril) once daily, and for children 2 to 11 years of age is 55 mcg (one spray in each nostril) once daily. Allegra® Nasal is not recommended for children under 2 years of age.

 

Allegra® Nasal Duo

 Allegra® Nasal Duo (Fluticasone Furoate 27.5 mcg and Azelastine Hydrochloride I.P. 140 mcg) is indicated for the treatment of symptoms of allergic rhinitis. It is indicated for the management of symptoms of allergic rhinitis, once the need for an antihistamine and corticosteroid has been established. It is recommended for the treatment of persistent, moderate to severe symptoms in adults and adolescents above 12 years of age.

Apidra®

Apidra® (Insulin Glulisine) is a recombinant human insulin analog – Fast acting. Apidra® should normally be used in regimens that include a longer-acting insulin or basal insulin analogue. Apidra® is administered subcutaneously.

Amaryl® M

Amaryl® M is fixed dose combination tablets of Metformin Hydrochloride Prolonged Release & Glimepiride. Amaryl® M is indicated for the management of patients with type 2 diabetes mellitus when diet, exercise and single agent (Glimepiride or Metformin alone) do not result in adequate glycemic control.

Amaryl® MP

Amaryl® MP is fixed dose combination tablets of Metformin Hydrochloride Sustained Release, Glimepiride & Pioglitazone Hydrochloride. Amaryl® MP is indicated as third line treatment of Type II diabetes mellitus in adult patients when diet, exercise and the single agents and second line therapy with two drugs do not result in adequate glycemic control.

Amaryl® MV

Amaryl® MV is fixed dose combination tablets of Metformin Hydrochloride (SR), Glimepiride & Voglibose. Amaryl® MV is indicated as third line treatment of Type II diabetes mellitus in adult patients when diet, exercise and the single agents and second line therapy with two drugs do not result in adequate glycemic control.
 

Amaryl® and Semi-Amaryl®

Semi-Amaryl® / Amaryl® is Glimepiride tablets which is an oral antidiabetic agent of the sulphonylurea group. Glimepiride is indicated for non-insulin dependent (type II) diabetes mellitus, whenever blood glucose levels cannot be controlled adequately by diet, physical exercise and weight reduction alone. Glimepiride may be combined with other, non-betacytotropic, oral antidiabetics. Glimepiride may also be used together with insulin (see dosage and administration).

 

 

 

 

 

Cardace®

Cardace® is Ramipril Tablets IP. Cardace® is indicated for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmHg or diastolic blood pressure > 90mmHg (or on antihypertensive treatment); total cholesterol >5.2mmol/L; HDL cholesterol < 0.9mmol/L; current smoker; known microalbuminuria; any evidence of previous vascular disease. Prevention of myocardial infarction, stroke or cardio-vascular death and reduction of need for revascularization procedures in patients with an increased cardiovascular risk such as manifest coronary heart disease, a history of stroke or a history of peripheral vascular disease. Treatment of patients who within the first few days after an acute myocardial infarction have demonstrated clinical signs of congestive heart failure. Treatment of hypertension and cardiac failure. Treatment of non-diabetic or diabetic overt glomerular or incipient nephropathy.

Cardace® AM

Cardace® AM is fixed dose combination of Ramipril and Amlodipine Tablets. Cardace® AM is indicated for the treatment of hypertension.

 

Cardace® H

Cardace® H is fixed dose combination of Ramipril & Hydrochlorothiazide Tablets IP. Cardace® H is indicated for the treatment of mild to moderate hypertension in patients (in whom combination therapy is appropriate) who have been stabilized on the individual components given in the same proportion.

Cardace® Meto

Cardace® Meto is fixed dose combination of Ramipril & Metoprolol Succinate Extended-Release Tablets. Cardace® Meto is indicated for the treatment of essential hypertension in adults.

 

 

Cardace® Protect

Cardace® Protect is fixed dose combination of Ramipril & Atorvastatin Tablets. Cardace® Protect is indicated for treatment of patients with both essential hypertension and hypercholesterolemia. Ramipril has been found to reduce risk of MI, stroke or cardiovascular death in patients with increased risk. Atorvastatin has been found to reduce the risk of MI, stroke, revascularization procedures and angina in patients with CHD.

Clexane®

Enoxaparin Sodium is a low molecular weight heparin (LMWH) that is administered subcutaneously and used as antithrombotic agent.
 

Frisium®

FRISIUM®, FRISIUM® Jr (Clobazam) is indicated in children, adults and elderly for Acute and chronic anxiety; as adjunctive therapy in patients with epilepsy who are not adequately stabilized with their anticonvulsant monotherapy.

Lantus®

Lantus® (Insulin glargine) is a novel recombinant human insulin analogue. It exhibits a peak less glucose-lowering profile with a prolonged duration of action.
Lantus® is administered subcutaneously.
 

Semi-Amaryl® M

Semi-Amaryl® M is fixed dose combination tablets of Metformin Hydrochloride Prolonged Release & Glimepiride. Semi-Amaryl® M is indicated as an adjunct to diet and exercise in Type 2 diabetes mellitus when monotherapy, is not able to achieve glycemic control.

Synvisc-One

Hylan® G-F 20 (Synvisc-One™) is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non pharmacologic therapy and to simple analgesics and for the treatment to decrease pain and discomfort allowing more extensive movement of the knee.
 

Targocid®

Targocid® is indicated in serious gram +ve infections, serious staphylococcal infections in patients sensitive or unresponsive to penicillins and cephalosporins, CAPD related peritonitis, prophylaxis in orthopaedic surgery at risk of gram +ve infections.

 

Thymoglobuline®

Thymoglobuline®, rabbit anti-human thymocyte immunoglobulin, is used for immunosuppression in kidney transplantation.


 

Toujeo®

Toujeo® (insulin glargine 300 U/ml) is a long-acting recombinant human insulin analogue. Toujeo® exhibits a more constant and prolonged glucose-lowering profile than U100 glargine. Toujeo® is administered subcutaneously. 

Valparin®

VALPARIN® (Valproate + Valproic Acid) is indicated for the treatment of generalized or partial epilepsy particularly with the following patterns of seizures: absence, myoclonic, tonic-clonic, atonic, mixed, as well as for partial epilepsy and manic episodes associated with bipolar disorder.

 

 

Vinlep

VINLEP™ (oxcarbazepine) is indicated as Monotherapy and adjunctive therapy in the treatment of partial seizures (which include seizure subtypes of simple, complex and partial seizures evolving to secondarily generalized seizures) in adult patients. Treatment of generalized tonic-clonic seizures in adults and children. Adjunctive therapy in the treatment of partial seizures in children aged 4 -16 years. Monotherapy in the treatment of partial seizures in children aged 4-16 years.

Vinlep Suspension

Vinlep™ Suspension (Oxcarbazepine) is indicated in adults and children aged 1 month and above for the treatment of :

  • Partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalized seizures)
  • Generalized tonic-clonic seizures
     

Disclaimer: The images depicted here are fictitious and meant for illustrative purpose only. Any resemblance to any person, living or dead is purely coincidental.